▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Aurinia Pharmaceuticals (NASDAQ: AUPH)

$8.24

(2.1%)

$0.17

Price as of May 20, 2025, 2:15 p.m. ET

Aurinia Pharmaceuticals Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
AUPH	+40.10%	-52.97%	-14.01%	+294%
S&P	+12.45%	+100.69%	+14.95%	+323%

Aurinia Pharmaceuticals Company Info

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

News & Analysis

The Fool has written over 100 articles on Aurinia Pharmaceuticals.

Featured Article

Why Aurinia Pharmaceuticals Stock Is Slumping Today

The biotech's premium valuation doesn't seem to be sitting well with investors.

George Budwell | Sep 18, 2023

Featured Article

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

The biotech's board is exploring strategic alternatives to boost shareholder value.

George Budwell | Jun 30, 2023

Why Aurinia Pharmaceuticals Stock Is Glowing Green Today

George Budwell | Apr 11, 2023

Investors appear to be cheering another patent win by the company.

Why Shares of Aurinia Pharmaceuticals Soared This Week

Jim Halley | Jan 6, 2023

A patent settlement and improved financials sent the stock soaring.

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

George Budwell | Aug 4, 2022

Investors embraced the biotech's second-quarter results.

Why Aurinia Pharmaceuticals Stock Is Sliding Today

Keith Speights | Jul 27, 2022

An analyst downgraded the stock.

Why Aurinia Pharmaceuticals Stock Is In Retreat Today

George Budwell | Jul 15, 2022

Investors are none too pleased with the company's recent slew of hires.

Why Aurinia Pharmaceuticals Stock Perked Up Today

George Budwell | Jul 1, 2022

Another buyout rumor is fueling the company's northward move today.

Valuation

Earnings Transcripts

Aurinia Pharmaceuticals Inc (AUPH) Q3 2021 Earnings Call Transcript

AUPH earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Nov 3, 2021

Aurinia Pharmaceuticals Inc (AUPH) Q2 2021 Earnings Call Transcript

AUPH earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 6, 2021

Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transcript

AUPH earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 25, 2021

Aurinia Pharmaceuticals Inc (AUPH) Q1 2020 Earnings Call Transcript

AUPH earnings call for the period ending March 31, 2020.

Motley Fool Transcribers | May 19, 2020

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services